Results 141 to 150 of about 1,457,629 (200)

The Bruton tyrosine kinase inhibitor CC-292 shows activity in mantle cell lymphoma and synergizes with lenalidomide and NIK inhibitors depending on nuclear factor-κB mutational status

open access: yesHaematologica, 2017
Anna Vidal-Crespo   +13 more
doaj   +1 more source

Scedosporium Brain Abscess: A Rare and Fatal Drawback of Bruton Tyrosine Kinase Inhibitor Therapy. [PDF]

open access: yesJ Hematol
Dalmazzo M   +10 more
europepmc   +1 more source

Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines. [PDF]

open access: yesBlood, 2021
Pleyer C   +13 more
europepmc   +1 more source

Bruton Tyrosine Kinase Inhibitor-Associated Pericardial Events by Agent and Generation.

open access: yesJAMA Netw Open
Serra VSB   +16 more
europepmc   +1 more source

Pre-existing cardiovascular disease is associated with an increased risk of cardiovascular events during Bruton tyrosine kinase inhibitor therapy. [PDF]

open access: yesOncologist
Fernandez Turizo MJ   +7 more
europepmc   +1 more source

Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial. [PDF]

open access: yesHaematologica
Shah NN   +34 more
europepmc   +1 more source

Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321). [PDF]

open access: yesJ Clin Oncol
Sharman JP   +27 more
europepmc   +1 more source

Efficacy and Safety Results With Rilzabrutinib, an Oral Bruton Tyrosine Kinase Inhibitor, in Patients With Immune Thrombocytopenia: Phase 2 Part B Study. [PDF]

open access: yesAm J Hematol
Cooper N   +17 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy